- Home
- OTLK vs CNF Comparison
OTLK vs CNF Comparison
Compare OTLK & CNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- CNF
- Stock Information
- Founded
- OTLK 2010
- CNF 1999
- Country
- OTLK United States
- CNF China
- Employees
- OTLK N/A
- CNF N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- CNF Finance: Consumer Services
- Sector
- OTLK Health Care
- CNF Finance
- Exchange
- OTLK Nasdaq
- CNF Nasdaq
- Market Cap
- OTLK 56.3M
- CNF 72.1M
- IPO Year
- OTLK 2016
- CNF 2018
- Fundamental
- Price
- OTLK $1.48
- CNF $0.86
- Analyst Decision
- OTLK Strong Buy
- CNF
- Analyst Count
- OTLK 5
- CNF 0
- Target Price
- OTLK $10.20
- CNF N/A
- AVG Volume (30 Days)
- OTLK 479.6K
- CNF 29.2K
- Earning Date
- OTLK 02-14-2025
- CNF 03-27-2025
- Dividend Yield
- OTLK N/A
- CNF N/A
- EPS Growth
- OTLK N/A
- CNF N/A
- EPS
- OTLK N/A
- CNF 0.24
- Revenue
- OTLK N/A
- CNF $109,788,152.00
- Revenue This Year
- OTLK N/A
- CNF N/A
- Revenue Next Year
- OTLK $288.46
- CNF $13.09
- P/E Ratio
- OTLK N/A
- CNF $4.25
- Revenue Growth
- OTLK N/A
- CNF 12.99
- 52 Week Low
- OTLK $0.87
- CNF $0.81
- 52 Week High
- OTLK $12.85
- CNF $2.84
- Technical
- Relative Strength Index (RSI)
- OTLK 40.05
- CNF 30.77
- Support Level
- OTLK $1.38
- CNF $1.05
- Resistance Level
- OTLK $1.51
- CNF $1.07
- Average True Range (ATR)
- OTLK 0.12
- CNF 0.07
- MACD
- OTLK 0.02
- CNF -0.02
- Stochastic Oscillator
- OTLK 38.86
- CNF 0.23
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.